Cargando…
Increased MCL1 dependency leads to new applications of BH3-mimetics in drug-resistant neuroblastoma
BACKGROUND: Neuroblastoma is a paediatric cancer that is characterised by poor prognosis for chemoresistant disease, highlighting the need for better treatment options. Here, we asked whether BH3-mimetics inhibiting BCL2 proteins may eliminate chemoresistant neuroblastoma cells. METHODS: We utilised...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646009/ https://www.ncbi.nlm.nih.gov/pubmed/37723317 http://dx.doi.org/10.1038/s41416-023-02430-8 |
_version_ | 1785134817221804032 |
---|---|
author | Jacob, Maureen Wiedemann, Sara Brücher, Daniela Pieper, Nadja M. Birkhold, Moni Särchen, Vinzenz Jeroch, Jan Demes, Melanie C. Gretser, Steffen Braun, Yannick Gradhand, Elise Rothweiler, Florian Michaelis, Martin Cinatl, Jindrich Vogler, Meike |
author_facet | Jacob, Maureen Wiedemann, Sara Brücher, Daniela Pieper, Nadja M. Birkhold, Moni Särchen, Vinzenz Jeroch, Jan Demes, Melanie C. Gretser, Steffen Braun, Yannick Gradhand, Elise Rothweiler, Florian Michaelis, Martin Cinatl, Jindrich Vogler, Meike |
author_sort | Jacob, Maureen |
collection | PubMed |
description | BACKGROUND: Neuroblastoma is a paediatric cancer that is characterised by poor prognosis for chemoresistant disease, highlighting the need for better treatment options. Here, we asked whether BH3-mimetics inhibiting BCL2 proteins may eliminate chemoresistant neuroblastoma cells. METHODS: We utilised cisplatin-adapted neuroblastoma cell lines as well as patient tissues before and after relapse to study alterations of BCL2 proteins upon chemoresistance. RESULTS: In a direct comparison of cisplatin-resistant cells we identified a prominent loss of sensitivity to BCL2/BCL-X(L) inhibitors that is associated with an increase in MCL1 dependency and high expression of MCL1 in patient tumour tissues. Screening of FDA-approved anti-cancer drugs in chemoresistant cells identified therapeutics that may be beneficial in combination with the clinically tested BH3-mimetic ABT263, but no synergistic drug interactions with the selective MCL1 inhibitor S63845. Further exploration of potential treatment options for chemoresistant neuroblastoma identified immunotherapy based on NK cells as highly promising, since NK cells are able to efficiently kill both parental and chemoresistant cells. CONCLUSIONS: These data highlight that the application of BH3-mimetics may differ between first line treatment and relapsed disease. Combination of NK cell-based immunotherapy with BH3-mimetics may further increase killing of chemoresistant neuroblastoma, outlining a new treatment strategy for relapsed neuroblastoma. |
format | Online Article Text |
id | pubmed-10646009 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-106460092023-09-19 Increased MCL1 dependency leads to new applications of BH3-mimetics in drug-resistant neuroblastoma Jacob, Maureen Wiedemann, Sara Brücher, Daniela Pieper, Nadja M. Birkhold, Moni Särchen, Vinzenz Jeroch, Jan Demes, Melanie C. Gretser, Steffen Braun, Yannick Gradhand, Elise Rothweiler, Florian Michaelis, Martin Cinatl, Jindrich Vogler, Meike Br J Cancer Article BACKGROUND: Neuroblastoma is a paediatric cancer that is characterised by poor prognosis for chemoresistant disease, highlighting the need for better treatment options. Here, we asked whether BH3-mimetics inhibiting BCL2 proteins may eliminate chemoresistant neuroblastoma cells. METHODS: We utilised cisplatin-adapted neuroblastoma cell lines as well as patient tissues before and after relapse to study alterations of BCL2 proteins upon chemoresistance. RESULTS: In a direct comparison of cisplatin-resistant cells we identified a prominent loss of sensitivity to BCL2/BCL-X(L) inhibitors that is associated with an increase in MCL1 dependency and high expression of MCL1 in patient tumour tissues. Screening of FDA-approved anti-cancer drugs in chemoresistant cells identified therapeutics that may be beneficial in combination with the clinically tested BH3-mimetic ABT263, but no synergistic drug interactions with the selective MCL1 inhibitor S63845. Further exploration of potential treatment options for chemoresistant neuroblastoma identified immunotherapy based on NK cells as highly promising, since NK cells are able to efficiently kill both parental and chemoresistant cells. CONCLUSIONS: These data highlight that the application of BH3-mimetics may differ between first line treatment and relapsed disease. Combination of NK cell-based immunotherapy with BH3-mimetics may further increase killing of chemoresistant neuroblastoma, outlining a new treatment strategy for relapsed neuroblastoma. Nature Publishing Group UK 2023-09-19 2023-11-09 /pmc/articles/PMC10646009/ /pubmed/37723317 http://dx.doi.org/10.1038/s41416-023-02430-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Jacob, Maureen Wiedemann, Sara Brücher, Daniela Pieper, Nadja M. Birkhold, Moni Särchen, Vinzenz Jeroch, Jan Demes, Melanie C. Gretser, Steffen Braun, Yannick Gradhand, Elise Rothweiler, Florian Michaelis, Martin Cinatl, Jindrich Vogler, Meike Increased MCL1 dependency leads to new applications of BH3-mimetics in drug-resistant neuroblastoma |
title | Increased MCL1 dependency leads to new applications of BH3-mimetics in drug-resistant neuroblastoma |
title_full | Increased MCL1 dependency leads to new applications of BH3-mimetics in drug-resistant neuroblastoma |
title_fullStr | Increased MCL1 dependency leads to new applications of BH3-mimetics in drug-resistant neuroblastoma |
title_full_unstemmed | Increased MCL1 dependency leads to new applications of BH3-mimetics in drug-resistant neuroblastoma |
title_short | Increased MCL1 dependency leads to new applications of BH3-mimetics in drug-resistant neuroblastoma |
title_sort | increased mcl1 dependency leads to new applications of bh3-mimetics in drug-resistant neuroblastoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646009/ https://www.ncbi.nlm.nih.gov/pubmed/37723317 http://dx.doi.org/10.1038/s41416-023-02430-8 |
work_keys_str_mv | AT jacobmaureen increasedmcl1dependencyleadstonewapplicationsofbh3mimeticsindrugresistantneuroblastoma AT wiedemannsara increasedmcl1dependencyleadstonewapplicationsofbh3mimeticsindrugresistantneuroblastoma AT brucherdaniela increasedmcl1dependencyleadstonewapplicationsofbh3mimeticsindrugresistantneuroblastoma AT piepernadjam increasedmcl1dependencyleadstonewapplicationsofbh3mimeticsindrugresistantneuroblastoma AT birkholdmoni increasedmcl1dependencyleadstonewapplicationsofbh3mimeticsindrugresistantneuroblastoma AT sarchenvinzenz increasedmcl1dependencyleadstonewapplicationsofbh3mimeticsindrugresistantneuroblastoma AT jerochjan increasedmcl1dependencyleadstonewapplicationsofbh3mimeticsindrugresistantneuroblastoma AT demesmelaniec increasedmcl1dependencyleadstonewapplicationsofbh3mimeticsindrugresistantneuroblastoma AT gretsersteffen increasedmcl1dependencyleadstonewapplicationsofbh3mimeticsindrugresistantneuroblastoma AT braunyannick increasedmcl1dependencyleadstonewapplicationsofbh3mimeticsindrugresistantneuroblastoma AT gradhandelise increasedmcl1dependencyleadstonewapplicationsofbh3mimeticsindrugresistantneuroblastoma AT rothweilerflorian increasedmcl1dependencyleadstonewapplicationsofbh3mimeticsindrugresistantneuroblastoma AT michaelismartin increasedmcl1dependencyleadstonewapplicationsofbh3mimeticsindrugresistantneuroblastoma AT cinatljindrich increasedmcl1dependencyleadstonewapplicationsofbh3mimeticsindrugresistantneuroblastoma AT voglermeike increasedmcl1dependencyleadstonewapplicationsofbh3mimeticsindrugresistantneuroblastoma |